Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 52 Issue 4, 2 April 2020

Building TADs in leukemia

The cover image depicts the creation of a 3D chromosomal landscape in a leukemia cell, described in Kloetgen et al. This study identifies a TAD fusion and separation events responsible for activation of oncogenes and silencing of tumor suppressors.

See Kloetgen et al.

Image: Molly Ferguson. Cover Design: Erin Dewalt.

Editorial

  • In 2015, the World Health Organization (WHO) issued guidelines for the naming of new human infectious diseases. The current global outbreak of the SARS-CoV-2 virus underscores the need to be accurate with our language, particularly as it relates to pandemics.

    Editorial

    Advertisement

Top of page ⤴

Comment

  • The African Orphan Crops Consortium promotes the strategic, genome-enabled improvement of under-researched crops for biodiversity-based, nutritious food solutions in Africa. The African Plant Breeding Academy empowers the continent’s plant breeders to apply advanced genetic approaches and shared genetic solutions to the task of tailoring the immense diversity of underutilized crops to the needs of Africa’s producers, processors and consumers.

    • Ramni Jamnadass
    • Rita H. Mumm
    • Allen Van Deynze
    Comment
Top of page ⤴

News & Views

  • Cancer cells have the extraordinary evolutionary potential to adapt and acquire resistance to most conventional and targeted therapies. In a new study, Lin et al., develop a systematic approach to identify combination therapies that produce cancer traps, in which evading the first drug makes the cancer vulnerable to the second.

    • Charles Y. Lin
    News & Views
Top of page ⤴

Perspectives

  • Combining genomic data with CRISPR, hiPSC and organoid technologies provides platforms to study the complex genetic architectures of brain disease. These studies could improve genetic diagnosis, drive drug discovery and move the field toward precision medicine.

    • Michael B. Fernando
    • Tim Ahfeldt
    • Kristen J. Brennand
    Perspective
Top of page ⤴

Letters

Top of page ⤴

Articles

Top of page ⤴

Analysis

Top of page ⤴

Amendments & Corrections

Top of page ⤴

Search

Quick links